U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some ... that are not exact copies are still legal. A federal judge March 5 denied a request ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Supply issues finally started to ease late in 2024, as compounded semaglutide — "copycats" of the patented stuff like Ozempic and Zepbound — began to flood the market when the FDA temporarily ...

Supply issues finally started to ease late in 2024, as compounded semaglutide — "copycats" of the patented stuff like Ozempic and Zepbound — began to flood the market when the FDA temporarily paused ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

Earlier this year, during a shortage of such drugs, it took advantage of a legal loophole that allowed it to (briefly ... the molecule in the other FDA-approved obesity jab, Eli Lilly's Zepbound. It's ...